Transdermal delivery of Chinese herbal medicine extract using dissolvable microneedles for hypertrophic scar treatment

Xiaoyu Ning\textsuperscript{a,b}, Christian Wiraja\textsuperscript{b}, Wan Ting Sharon Chew\textsuperscript{a,b}, Chen Fan\textsuperscript{c}, Chenjie Xu\textsuperscript{a,b,d,*}

\textsuperscript{a}NTU Institute for Health Technologies, Interdisciplinary Graduate Group, Nanyang Technological University, Singapore 639798, Singapore
\textsuperscript{b}School of Chemical and Biomedical Engineering, Nanyang Technological University, Singapore 637459, Singapore
\textsuperscript{c}Skin Research Institute of Singapore, 8A Biomedical Grove, Singapore 138648, Singapore
\textsuperscript{d}Department of Biomedical Engineering, City University of Hong Kong, Hong Kong SAR 999077, China

Received 26 November 2020; received in revised form 15 January 2021; accepted 6 February 2021

\textbf{KEY WORDS}
Traditional Chinese medicine; Shikonin; Hyaluronic acid; Microneedle; Hypertrophic scarring; Drug delivery; Transdermal delivery; Skin

\textbf{Abstract} Hypertrophic scars are unfavorable skin diseases characterized by excessive collagen deposition. Although systemic treatments exist in clinic to manage hypertrophic scars, they pose significant side effects and tend to lose efficacy over prolonged applications. Traditional Chinese medicine (TCM) offers as a promising candidate to treat pathological scars. A large number of TCMs have been studied to show anti-scarring effect, however, the natural barrier of the skin impedes their penetration, lowering its therapeutic efficacy. Herein, we reported the use of dissolvable hyaluronic acid (HA) microneedles (MNs) as a vehicle to aid the transdermal delivery of therapeutic agent, a model TCM called shikonin for the treatment of hypertrophic scars. Here, shikonin was mixed with HA to make MNs with adequate mechanical strength for skin penetration, making its dosage controllable during the fabrication process. The therapeutic effect of the shikonin HA MNs was studied \textit{in vitro} using HSFs and then further verified with quantitative reverse transcriptase polymerase chain reaction. Our data suggest that the shikonin HA MNs significantly reduce the viability and proliferation of the HSFs and downregulate the fibrotic-related genes (\textit{i.e.}, \textit{TGF\beta1}, \textit{FAP-\alpha} and \textit{COL1A1}). Furthermore, we observed a localized therapeutic effect of the shikonin HA MNs that is beneficial for site-specific treatment.

*Corresponding author.
E-mail address: chenjie.xu@cityu.edu.hk (Chenjie Xu).

Peer review under responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

https://doi.org/10.1016/j.apsb.2021.03.016
2211-3835 © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Hypertrophic scars are characterized by excessive collagen deposition by dermal fibroblasts. The underlying causes remain elusive, although ethnicity and genetic predisposition play a role. Current treatments, including corticosteroids, pressure therapy, laser therapy and surgical operation, are not satisfactory and may cause significant side effects over prolonged use. For instance, intraliesional corticosteroid injection is the first-line approach for physicians to prevent and treat the keloids and hypertrophic scars. While it provides a 50%–100% flattening of the keloids, it requires multiple painful injections, and many cause hypopigmentation and skin atrophy with 9%–50% recurrence rate. Surgical removal of scars could be temporarily gratifying; however, it is normally followed by more aggressive regrowth of the scar unless other therapies were performed post-surgery. This complicates the treatment and requires exemplary persistence from the patients.

With rich resource and relatively low cost, traditional Chinese medicines (TCMs) have been widely used for thousands of years in prevention and treatment of many diseases including scarring. Sourced from the nature and typically possessed little side effects, TCMs emphasize on improving the general health of patients. A large amount of TCMs have been studied to display anti-scarring effect. However, the natural skin barrier such as stratum corneum and the compact structure of scar tissues limit the permeation and efficiency of TCM on cutaneous diseases. Although reformulation through microemulsion or nanoparticles has been found to improve the penetration of TCM, they introduce additional components which alter the original TCM structure and interfere with its functionality and toxicity. For instance, the microemulsion product of oxametrine-phospholipid complex (OMT-PLC) consists of not only 10.0% OMT-PLC, but also 8.0% isopropyl myristate, 30.0% cremophor RH40/polyethyleneglycol 400 (1:1) and 52.0% water. In addition, when TCMs are nanomaterialized, the physicochemical properties of the active ingredient might be altered, diminishing its therapeutic efficacy.

Microneedle (MN) technology is effective in delivering various drugs intradermally without affecting blood vessels and nerves. It overcomes the protective stratum corneum of the epidermis layer and creates transient micro holes on the skin to aid the permeation of the drugs. Many studies have shown MN’s potential to successfully deliver therapeutic agents including oligonucleotide, vaccine, peptide and so on.

Thus, we believe the transdermal delivery of TCM formulations utilizing MNs would address the limitations met currently in clinics. As a proof-of-concept, we chose shikonin as a model TCM drug. Shikonin is an active component extracted from Arnebiae Radix (ZiCao) and has been demonstrated to inhibit cell viability, cell proliferation and collagen production in scar-derived fibroblasts, thus offering a promising alternative for the treatment of scars. It is generally mixed in oil-based creams or ointments before application to human skin, however, achieving high bioavailability is challenging due to its insolubility in water. The transdermal delivery of shikonin with MN platform offers a promising route to enhance its bioavailability.

Herein, we incorporate shikonin into MN made from dissolveable hyaluronic acid (HA) to aid the delivery. HA is widely distributed throughout our tissues, offering excellent biocompatibility with minimal side effects. Shikonin was pre-dissolved in Dimethyl sulfoxide (DMSO) before mixing with HA solution and the mixture solution was then used to make MNs by micro molding. The amount of shikonin encapsulated in the MN could be easily controlled during the fabrication process by adjusting the pre-dissolved shikonin concentrations. Our previous study indicated that shikonin could inhibit cell proliferation, induce apoptosis of hypertrophic scar derived fibroblast (HSF), and attenuate transdermal growth factor beta 1 (TGFβ1)-induced collagen production. In this study, the efficiency of shikonin in killing the HSF and attenuating scar-related gene expressions was maintained after incorporating into HA MNs. Moreover, shikonin-MNs offers a localized therapeutic effect that is beneficial for site-specific scar treatment.

2. Methods

2.1. Materials

All chemicals and reagents were obtained from Sigma–Aldrich (Singapore) except mentioned otherwise. The stainless-steel master mold of MN (300 μm base diameter, 5 μm tip radius, and 1000 μm height) was purchased from Micropoint Technologies Pte Ltd. (Singapore). Hyaluronic acid (HA, 300 kDa) was purchased from Freda Biochem Co., Ltd. (China). Phosphate buffered saline (1×, PBS), high glucose (4.5 g/L) Dulbecco’s modified Eagle’s medium (DMEM) were obtained from Lonza. Fetal bovine serum (FBS), Trypsin–EDTA (0.05%), and penicillin–streptomycin (10,000 U/mL) were purchased from Gibco (Singapore). AlarmarBlue cell viability reagent was purchased from Thermofisher (Singapore). TRizol reagent was obtained from Invitrogen (Singapore). iScript Adv cDNA kit & Universal SYBR® Green Supermix were purchased from Biorad (Singapore).

2.2. Fabrication of the PDMS mold

The fabrication of the PDMS mold followed our previous methodology. Briefly, the PDMS daughter mold was produced by pouring PDMS into a Petri dish containing stainless steel mother molds. Degassing was performed by vacuum oven and subsequently, curing was performed at 70 °C for 1 h. PDMS molds that reversely replicate the mother molds were obtained by detaching the cured PDMS from the Petri dish.
2.3. Fabrication of the shikonin HA MN

Shikonin was first dissolved in DMSO with a concentration of 50 mg/mL as stock solution for subsequent experiments. HA powder was dissolved in deionized (DI) water and mixed homogeneously before different amounts of shikonin stock were added to a final concentration of 0, 4, 20, 100 and 200 μg/mL. The shikonin–HA mixtures were then poured into PDMS molds and followed by centrifugation (3200 g, 5 min) to fill the tips of the MN completely and remove air bubbles. More mixtures were then topped up into the PDMS mold to form the MN base. The drying process was conducted in fume hood under room temperature.

2.4. Loading efficiency of shikonin HA MN

Shikonin HA MNs (made from different shikonin mixture concentrations) were thoroughly dissolved in PBS at 37 °C. Subsequently, the solution was mixed gently to ensure homogeneous solution. Shikonin distribution was read under a microplate reader (SpectraMax M5, Molecular Devices) at λ = 520 nm. Solution absorbance was fitted against a standard curve to calculate the concentration of shikonin.

2.5. Compression test of shikonin HA MN

The compression test was done with a Tensile Meter (Instron 5543). HA MNs containing varying amounts of shikonin were placed on the specimen plate with tips facing upwards. The displacement versus the load were measured and recorded until a preset maximum loading force of 80 N was reached.

2.6. Ex vivo penetration test

HA MNs containing the highest shikonin (made from 200 μg/mL shikonin HA solution) was thumb-pressed into an excised porcine skin and held steadily for 3 min. Subsequently, the treated skin was cryo-sectioned and hematoxylin & eosin (H&E)-stained for histological analysis.

2.7. Fibroblast cell culture

Fibroblasts derived from hypertrophic scar tissue (HSFs) were cultured in high-glucose DMEM with 10% FBS and 1% penicillin–streptomycin in a humidified condition of 37 °C with 5% CO2. Culture medium was replaced every 2 days and cells were sub-cultured when they reached 95% confluence.

2.8. Biocompatibility assessment of HA

The biocompatibility of blank HA MN was investigated using live/dead staining kit which contains calcein-AM and propidium iodide (PI) to stain viable and dead cells, respectively. HA MNs were placed and incubated for 24 h on HSFs when the cells reached 80% confluency in the well plate. The live/dead staining solution was then added as per the manufacturer’s instructions and incubated in 37 °C for 15 min. Fluorescence images were taken by a digital microscope (Leica DVM6) at λ_{ex} = 490 nm and λ_{em} = 515 nm for live signal and λ_{ex} = 535 nm, λ_{em} = 617 nm for dead signal.

The biocompatibility of HA solutions (0.125, 0.5, 2 and 4 mg/mL) were investigated using the AlamarBlue assay. In accordance with the manufacturer’s protocols, the AlamarBlue reagent was added to cells following 24 h treatment of HA solutions (initial confluency of 60%) and left incubated for 2 h before microplate reading (λ_{ex} = 560 nm, λ_{em} = 590 nm). The normalized metabolism rate was determined by normalizing the fluorescence intensities with that of untreated group.

2.9. Efficacy of shikonin HA MNs on HSFs

Four groups were investigated in the test including an untreated group, TGFβ1 treated group, TGFβ1 & shikonin solution treated group and TGFβ1 & shikonin HA MN-treated group. The MNs were segmented to ensure the same amount of shikonin were added in the cell culture plate as the shikonin solution group. Above-mentioned treatments were applied to HSFs (80% confluency) for 24 and 48 h. Subsequently, live/dead staining and fluorescence imaging followed as described above. Cell viability rate was then calculated by counting the numbers of live and dead cells in ImageJ. Moreover, cell metabolism rate following 24 h of treatment were assessed with AlamarBlue assay as described above.

2.10. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR)

To assess the modulation of fibrotic genes on HSFs undergoing shikonin HA MN treatment, cells underwent the treatments...
mentioned above for 24 h and suspended and lysed with TRIzol. Following RNA isolation through ethanol precipitation, cDNA conversion was performed using the iScript Adv cDNA kit according to the manufacturer’s protocol. Primer sequences for TGFβ1, FAP-α, and COL1A1 mRNA were obtained and verified from previous studies. CT values were obtained through qPCR with CFX Connect PCR System (Biorad) and 2^−ΔΔCT expression was utilized to calculate the change in fold expression.

2.11. Preparation of 3D in vitro cell model

HSF cell suspension (5 × 10^6 cells/mL) in culture media was mixed gently with 2.8% of warm agarose solution at 1:1 volume ratio and settled to solidify for 5 min inside the well plate before topping up additional culture media. Cells in agarose hydrogel were incubated for 24 h prior to shikonin HA MN application. The MNs were gently inserted into the hydrogel and the live/dead staining were performed after 24 h of treatment. Following which, 3D fluorescence images were obtained using the Z-stack function of a confocal microscope (Zeiss LSM 800). Viability of the 3D cultured cells was then assessed by quantifying the live/dead signals at 3 different Z-positions.

2.12. Statistical analysis

Data normalization (when applicable) is presented individually in associated figure legend. One-way ANOVA was employed to calculate the significant P values. A suitable post-hoc test was chosen using the IBM SPSS Statistics 22 software (Tukey). In each experiment, values were reported as mean ± standard deviation of 4 samples. Unless stated otherwise, N.S. represents non-significance, *P < 0.05, **P < 0.01, and ***P < 0.001.

3. Results and discussion

HA (300 KDa) was chosen to make the dissolvable MNs. Shikonin was pre-dissolved in DMSO to make a stock solution before mixed with HA solution (50 mg/mL). With this mixture, shikonin HA MNs were made in polydimethylsiloxane (PDMS) mold through a two-step process, where the tips and base of MNs were made consecutively (Scheme 1). The dosage of shikonin loaded in the MNs were reflected by the color of the MN patches (Fig. 1A). While blank MNs are transparent, darker color of the MNs indicates higher dosage of shikonin. The exact dosage of shikonin in the shikonin HA MNs was quantified through MN dissolution and measurement of shikonin absorbance at λ = 520 nm (Fig. 1B). At the highest loading concentration, 30.76 ± 0.98 μg shikonin was

![Figure 1](https://example.com/figure1.png)

Figure 1 Characterization of the Shikonin HA MN patches. (A) Photographic images of the HA MN patches loaded with various amount of Shikonin. From left to right: 0, 4, 20, 100, and 200 μg/mL Shikonin solution was mixed with HA during molding. Scale bar: 2 mm. (B) Quantification of Shikonin loading in each MN patch in (A). (C) Representative microscopic image of a single tip of Shikonin HA MN patch. Scale bar: 100 μm. (D) Scanning electron microscopic image of the MN in (C). Scale bar: top: 100 μm, bottom: 10 μm. (E) Load/needle versus displacement curve of the MNs made from different Shikonin HA solution. (F) H&E staining image of the pig skin after MN (SHI-200-HA) treatment showing micro hole being created by MN. Scale Bar: 0.5 mm.
carried per MN patch (100 MN tips). The delivery of 1 μg of
shikonin every 2 days could effectively treat a burn wound created
on porcine with a diameter of 5 cm to remediate hypertrophic scar17. Therefore, we achieved a significantly greater loading if
one MN patch is used per dosage. Furthermore, considering the
patch size (∼1 cm²) is considerably smaller than a 5 cm wound
(area ∼20 cm²), we could simply enlarge the MN size or apply
several MN (3–4) to achieve greater shikonin delivery dosage. In
overall, we believe that the proposed shikonin MN can meet the
dosage requirement for clinical applications.

The shikonin HA MN has a pyramidal shape with the height
and base dimension of 1000 and 300 μm, respectively (Fig. 1C
and D). Shikonin HA MNs showed the typical elastic deformation
under the compression test (Fig. 1E). The minimum force required
for MN to penetrate the live skin was proven to be 0.058 N/
needle29. As these shikonin HA MNs were strong enough to
withstand a force of more than 0.7 N/needle without fracture, we
were able to puncture ex vivo porcine skin without any difficulty
(Fig. 1F).

HA is well known for its biocompatibility. Nevertheless, we
had to ascertain the overall effect of the blank HA MN (beyond
strictly physical or chemical properties28) to distinguish and
evaluate the therapeutic effects exerted by the loaded shikonin. In
this case, the toxicity of the HA MNs on HSFs were first examined
to distinguish the therapeutic efficacy of shikonin. The HA MNs
show negligible toxicity to the HSFs as very few dead cells were
observed from the live/dead staining (Fig. 2A). HSFs treated with
0.125 mg/mL HA showed slight increase in metabolism rate while
the other groups (0.5, 2 and 4 mg/mL HA) showed lower meta-
bolism rate as compared to the untreated group. Nevertheless, the
altered metabolism rate on HSFs is minimal, with ∼90% retained
even at the highest 4 mg/mL treatment (Fig. 2B), indicating the
safety and biocompatibility of HA as an excipient.

To assess the apoptosis-inducing ability of shikonin HA MN on
HSFs, the viability of TGFβ1-stimulated HSFs following shikonin
HA MN treatment (TGFβ1 + Shi HA MN) was compared with
untreated group (UT), TGFβ1-activated group (TGFβ1) and shi-
konin solution treated group (TGFβ1 + shikonin). According to
our previous study, a concentration of 1 μg/mL shikonin is suf-
cient for inducing apoptosis on HSFs. Thus, we performed the
subsequent cell studies with shikonin HA MN made from
20 μg/mL shikonin solution. Live/dead staining was performed
after 24 and 48 h of treatment (Fig. 3A and Supporting
Information Fig. S1). After 24 h of treatment, HSFs treated with
MNs started to show cell death while those treated by shikonin
solution showed significantly altered cell morphology, where the
cells partially shrank and change from the original spindle shape
to round shape. After 48 h, the viability rate in shikonin solution
group is comparable with that in shikonin HA MN group. Notably,
compared to the homogenous killing effect observed for the shi-
konin solution group, shikonin HA MN-treated group showed
localized killing of cells in close proximity with the MN. Mean-while, cells further away from the MNs have good viability even
after 48 h of treatment (Supporting Information Fig. S2). Release
of shikonin from the MN is associated with the HA tips dissolu-
tion. Therefore, cells located in the vicinity of the MNs are
exposed to higher amount of shikonin. This is corroborated with
more effective killing of cells after 24 h of treatment for shikonin
HA MN group, relative to the shikonin solution group in which
shikonin was homogeneously distributed throughout the well
plate. Such localized cytotoxicity is beneficial for scar treatment,
to minimize undesirables side-effects on healthy skin in its vicinity.

To examine the effect of shikonin HA MNs on the proliferation
of TGFβ1 stimulated HSFs, the same groups were tested by
AlamarBlue proliferation assay and the results were standardized
by the untreated group (UT, Fig. 4A). The addition of TGFβ1
activated and enhanced the proliferation rate of HSFs to 108.27 ±
0.93%. Meanwhile, shikonin solution and shikonin HA
MN group significantly reduced the proliferation rate of the TGFβ1-
stimulated HSFs to 34.14 ± 0.66% and 35.58 ± 5.57%, respec-
tively. This data indicates that shikonin HA MNs could override
the TGFβ1-mediated HSF activation.

TGFβ1, fibroblast activation protein, alpha (FAP-α) and
collagen, type I, alpha 1 (COL1A1) are genes closely related to
scar formation. In detail, TGFβ1 improves myofibroblasts differ-
entiation and stimulates the collagen synthesis21, FAP-α is up-
regulated in scar tissue and most intensively expressed in keloid22,
while COL1A1 is the gene encoding collagen type I and found to
promote hypertrophic scar formation23. Thus, inhibition of the
scar-related gene expression is a potential way to mitigate tissue
scarring24. Therefore, we evaluate the modulation of these genes
after 24 h of shikonin or shikonin HA MN treatment (Fig. 4B).

The results show that TGFβ1 stimulation upregulated the
expression of the above-mentioned genes and that shikonin

Figure 2  Biocompatibility assessment of blank HA MN. (A) Representative images showing cell morphology and Live/Dead staining (live: green; dead: red) of HSFs treated with blank HA MN. Scale bar: 100 μm. (B) AlamarBlue metabolism assay showcase minimal toxicity of HA even up to 4 mg/mL concentration. Error bars indicate the mean ± SD (n = 4). *P < 0.05 versus the untreated control. Statistical analysis was performed using one-way ANOVA test.
suppresses the TGFβ1-induced upregulations of those genes in HSFs. The gene expressions in the shikonin HA MN-treated group was comparable to that of the shikonin solution treated group, suggesting that the encapsulation of shikonin with HA MNs did not alter the functionality of shikonin in modulating these scar genes.

Figure 3  Examination of the Shikonin HA MN killing efficiency on TGFβ1 treated HSF. (A) Microscopic fluorescence (Live/Dead staining) and BF images of HSF treated by different groups after 24 h of incubation. Scale bar: 200 μm. (B) Quantified viability rate following treatment application for 24 & 48 h. Error bars indicate the mean ± SD (n = 3). **P < 0.01 versus the TGFβ1 group, N.S. means not significant. Statistical analysis was performed using one-way ANOVA test.

Figure 4  Functionality assay of the Shikonin on TGFβ1 treated HSF. (A) Alamarblue assay demonstrate significant mitigation of cell metabolism from Shikonin-treated groups. Error bars indicate the mean ± SD (n = 4). **P < 0.01, ***P < 0.001 versus the TGFβ1 group. Statistical analysis was performed using one-way ANOVA test. (B) PCR assessment shows downregulated fibrotic genes (i.e., TGFβ1, FAP-α and COL1A1 mRNA) following Shikonin application, reversing the upregulation induced by TGFβ1 addition. Error bars indicate the mean ± SD (n = 3). *P < 0.05 versus the TGFβ1 group. N.S. P > 0.05 between groups treated with Shikonin solution and Shikonin HA MNs. Statistical analysis was performed using one-way ANOVA test.
To further clarify the localized efficacy that the MNs endow to shikonin, a 3D cell culture model was established by incorporating HSFs in 1.4% agarose followed by the treatment of shikonin HA MNs. The 3D live/dead staining images show a significantly higher dead signal in area in vicinity of MN as compared to the edge area (Fig. 5A). Further quantification of the fluorescence signals show a significantly lower viability of HSFs in MN tips area than that of the edge area (≈50%; Fig. 5B). This data is consistent with our 2D culture tests and confirm the localized killing effect of shikonin HA MN.

4. Conclusions

This study aimed to incorporate shikonin into dissolvable HA MN to aid its intradermal delivery for scar treatment. The HA MN showed negligible toxicity to HSFs and different amount of shikonin could be loaded into HA MNs by simply altering the shikonin concentration in the mixture during fabrication. The mechanical performance and surface morphology of the MNs were minimally affected by the addition of shikonin, and the fabricated shikonin HA MNs can withstand a force higher than 0.7 N/needle without fracture and successfully puncture the porcine skin. The fabricated shikonin HA MN can modulate the viability, and metabolism rate of TGFβ1-treated HSFs. Moreover, a localized treatment effect was observed from the shikonin HA MN which is beneficial for the site-specific scar treatment in clinic. In addition, the expression of scar-related genes (TGFβ1, FAP-α and COL1A1) were also attenuated by the treatment of shikonin HA MNs. Taken together, shikonin HA MN possesses great potential for topical scar treatment.

Acknowledgments

Chenjie Xu acknowledges the funding support from Singapore Agency for Science, Technology and Research (A•STAR) Science and Engineering Research Council Additive Manufacturing for Biological Materials (AMBM) program (A18A8b0059, Singapore), City University of Hong Kong (#9610472, China), General Research Fund (GRF) from University Grant Committee of Hong Kong (UGC) Research Grant Council (RGC) (#9042951, China), and NSFC/RGC Joint Research Scheme (N_CityU118/20, China).

Author contributions

Chenjie Xu and Xiaoyu Ning designed the research. Xiaoyu Ning carried out the experiments and performed data analysis. Christian Wiraja and Sharon Chew Wan Ting participated part of the experiments. Xiaoyu Ning wrote the manuscript. Fan Chen and Christian Wiraja gave comments on the manuscript. Chenjie Xu revised the manuscript. All of the authors have read and approved the final manuscript.

Conflicts of interest

The authors have no conflicts of interest to declare.

Appendix A. Supporting information

Supporting data to this article can be found online at https://doi.org/10.1016/j.apsb.2021.03.016.

References

1. Rabello FB, Souza CD, Farina Júnior JA. Update on hypertrophic scar treatment. *Clinics* 2014;69:565–73.
2. Juckett G, Hartman-Adams H. Management of keloids and hypertrophic scars. *Am Fam Physician* 2009;80:253–60.
3. Niessen FB, Spauwen PH, Schalkwijk J, Kon M. On the nature of hypertrophic scars and keloids: a review. *Plast Reconstr Surg* 1999;104:1435–58.
4. Hou Q, He WJ, Hao HJ, Han QW, Chen L, Dong L, et al. The four-herb Chinese medicine ANBP enhances wound healing and inhibits scar formation via bidirectional regulation of transformation growth factor pathway. *PLoS One* 2014;9:e112274.
5. Ye Q, Wang SJ, Chen JY, Rahman K, Xin HL, Zhang H. Medicinal plants for the treatment of hypertrophic scars. *Evid Based Complement Alternat Med* 2015;2015:101340.
6. Wu Y, Yan G, Cui B. Advances in studies on nano-technology applied in Chinese Materia Medica. *Chin Tradit Herb Drugs* 2011;42:403–8.
7. Cao FH, OuYang WQ, Wang YP, Yue PF, Li SP. A combination of a microemulsion and a phospholipid complex for topical delivery of oxymatrine. *Arch Pharm Res (Seoul)* 2011;34:551.
8. Waghule T, Singhvi G, Dubey SK, Pandey MM, Gupta G, Singh M, et al. Microneedles: a smart approach and increasing potential for transdermal drug delivery system. *Biomed Pharmacother* 2019;109:1249–58.
9. Ning X, Wiraja C, Lio DCS, Xu C. A Double-layered microneedle platform fabricated through frozen spray-coating. Adv Healthcare Mater 2020;9:2000147.

10. Zheng M, Wiraja C, Yeo DC, Chang H, Lio DCS, Shi W, et al. Oligonucleotide molecular sprinkler for intracellular detection and spontaneous regulation of mRNA for theranostics of scar fibroblasts. Small 2018;14:1802546.

11. Xie Y, Fan C, Dong Y, Lynam E, Leavesley DI, Li K, et al. Functional and mechanistic investigation of Shikonin in scarring. Chem Biol Interact 2015;228:18–27.

12. Albreht A, Vovk I, Simonovska B. Addition of beta-lactoglobulin produces water-soluble shikonin. J Agric Food Chem 2012;60:10834–43.

13. Gupta RC, Lall R, Srivastava A, Sinha A. Hyaluronic acid: molecular mechanisms and therapeutic trajectory. Front Vet Sci 2019;6:192.

14. Fan C, Xie Y, Dong Y, Su Y, Upton Z. Investigating the potential of Shikonin as a novel hypertrophic scar treatment. J Biomed Sci 2015;22:70.

15. Fan C, Dong Y, Xie Y, Su Y, Zhang X, Leavesley D, et al. Shikonin reduces TGF-beta 1-induced collagen production and contraction in hypertrophic scar-derived human skin fibroblasts. Int J Mol Med 2015;36:985–91.

16. Yeo D, Wiraja C, Miao Q, Ning X, Pu K, Xu C. Anti-scarring drug screening with near-infrared molecular probes targeting fibroblast activation protein-α. ACS Appl Bio Mater 2018;1:2054–61.

17. Dahiri G, Tumbarello DA, Turner CE, Van de Water L. Hic-5 promotes the hypertrophic scar myofibroblast phenotype by regulating the TGF-beta 1 autocrine loop. J Invest Dermatol 2008;128:2518–25.

18. Deng X, Chen Q, Qiang L, Chi M, Xie N, Wu Y, et al. Development of a porcine full-thickness burn hypertrophic scar model and investigation of the effects of shikonin on hypertrophic scar remediation. Front Pharmacol 2018;9:590.

19. Lee C, Yang H, Kim S, Kim M, Kang H, Kim N, et al. Evaluation of the anti-wrinkle effect of an ascorbic acid-loaded dissolving microneedle patch via a double-blind, placebo-controlled clinical study. Int J Cosmet Sci 2016;38:375–81.

20. de Moraes Porto I. Polymer biocompatibility, polymerization. London: IntechOpen Ltd.; 2012.

21. Penn JW, Grobbelaar AO, Rolfe KJ. The role of the TGF-β family in wound healing, burns and scarring: a review. Int J Burns Trauma 2012;2:18–28.

22. Diemus K, Bayat A, Gilmore BF, Seifert O. Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: implications for development of a novel treatment option. Arch Dermatol Res 2010;302:725–31.

23. Bi S, Chai L, Yuan X, Cao C, Li S. MicroRNA-98 inhibits the cell proliferation of human hypertrophic scar fibroblasts via targeting Col1A1. Biol Res 2017;50:22.

24. Fan C, El Andaloussi S, Lehto T, Kong KW, Seow Y. Smad-binding decoy reduces extracellular matrix expression in human hypertrophic scar fibroblasts. Mol Med Rep 2020;6:4589–600.